looks like sales are going in the wrong direction. the one thing this company needs is a buyout by a company with a educated and seasoned sales force that already has a good reputation and a in with the doctors. If sales come in half of same quarter last year we will easy be looking at a 12-13 dollar share price.
I thought management stated their goals were get the product to as many patients that need it and shareholder value.
I guess they were just kidding. Next up....further dilution.
Market Data 
Markets 
AI
